temozolomide has been researched along with Brain Edema in 12 studies
Brain Edema: Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is a phase-I study of gefitinib in combination with temozolomide in patients with gliomas." | 9.13 | Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ( Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK, 2008) |
| " Food and Drug Administration and EMA-approved xCT inhibitor, sulfasalazine (SAS) in gliomas." | 7.83 | Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. ( Buchfelder, M; Dörfler, A; Engelhorn, T; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Klucken, J; Minakaki, G; Rauh, M; Savaskan, N; Sehm, T, 2016) |
| "Temozolomide (TMZ) is used for treating glioblastoma." | 5.35 | Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in human glioblastoma T98G and U87MG cells. ( Banik, NL; Das, A; Ray, SK, 2008) |
| "This is a phase-I study of gefitinib in combination with temozolomide in patients with gliomas." | 5.13 | Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ( Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK, 2008) |
| " Food and Drug Administration and EMA-approved xCT inhibitor, sulfasalazine (SAS) in gliomas." | 3.83 | Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. ( Buchfelder, M; Dörfler, A; Engelhorn, T; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Klucken, J; Minakaki, G; Rauh, M; Savaskan, N; Sehm, T, 2016) |
| "Cerebral edema was assessed at 4, 12, 22 and 34 weeks post-surgery, together with steroids consumption and patients' psychological status." | 2.90 | A novel lecithin-based delivery form of Boswellic acids as complementary treatment of radiochemotherapy-induced cerebral edema in patients with glioblastoma multiforme: a longitudinal pilot experience. ( Bertuccioli, A; Botta, L; Bruzzone, MG; Cuccarini, V; Di Pierro, F; Fariselli, L; Lamperti, E; Petruzzi, A; Simonetti, G, 2019) |
| "Additionally, there is evidence that treatment-related necrosis occurs more frequently and earlier after temozolomide chemotherapy than after radiotherapy alone." | 2.44 | Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. ( Brandsma, D; Sminia, P; Stalpers, L; Taal, W; van den Bent, MJ, 2008) |
| "Temozolomide (TMZ) is used for treating glioblastoma." | 1.35 | Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in human glioblastoma T98G and U87MG cells. ( Banik, NL; Das, A; Ray, SK, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Li, F | 1 |
| Zhang, Y | 1 |
| Wang, N | 1 |
| Song, C | 1 |
| Gao, Y | 1 |
| Diao, X | 1 |
| Zhang, H | 1 |
| Bale, TA | 1 |
| Sait, SF | 1 |
| Benhamida, J | 1 |
| Ptashkin, R | 1 |
| Haque, S | 1 |
| Villafania, L | 1 |
| Sill, M | 1 |
| Sadowska, J | 1 |
| Akhtar, RB | 1 |
| Liechty, B | 1 |
| Juthani, R | 1 |
| Ladanyi, M | 1 |
| Fowkes, M | 1 |
| Karajannis, MA | 1 |
| Rosenblum, MK | 1 |
| Di Pierro, F | 1 |
| Simonetti, G | 1 |
| Petruzzi, A | 1 |
| Bertuccioli, A | 1 |
| Botta, L | 1 |
| Bruzzone, MG | 1 |
| Cuccarini, V | 1 |
| Fariselli, L | 1 |
| Lamperti, E | 1 |
| Li, HL | 1 |
| Cui, XL | 1 |
| Zhang, JN | 1 |
| Lin, S | 1 |
| Pramanik, PP | 1 |
| Parmar, HA | 1 |
| Mammoser, AG | 1 |
| Junck, LR | 1 |
| Kim, MM | 1 |
| Tsien, CI | 1 |
| Lawrence, TS | 1 |
| Cao, Y | 1 |
| Sehm, T | 1 |
| Fan, Z | 1 |
| Ghoochani, A | 1 |
| Rauh, M | 1 |
| Engelhorn, T | 1 |
| Minakaki, G | 1 |
| Dörfler, A | 1 |
| Klucken, J | 1 |
| Buchfelder, M | 1 |
| Eyüpoglu, IY | 1 |
| Savaskan, N | 1 |
| Choi, SH | 1 |
| Kim, JW | 1 |
| Chang, JS | 1 |
| Cho, JH | 1 |
| Kim, SH | 1 |
| Chang, JH | 1 |
| Suh, CO | 1 |
| Matuschek, C | 1 |
| Bölke, E | 1 |
| Nawatny, J | 1 |
| Hoffmann, TK | 1 |
| Peiper, M | 1 |
| Orth, K | 1 |
| Gerber, PA | 1 |
| Rusnak, E | 1 |
| Lammering, G | 1 |
| Budach, W | 1 |
| de Wit, MC | 1 |
| de Bruin, HG | 1 |
| Eijkenboom, W | 1 |
| Sillevis Smitt, PA | 1 |
| van den Bent, MJ | 2 |
| Prados, MD | 1 |
| Yung, WK | 1 |
| Wen, PY | 1 |
| Junck, L | 1 |
| Cloughesy, T | 1 |
| Fink, K | 1 |
| Chang, S | 1 |
| Robins, HI | 1 |
| Dancey, J | 1 |
| Kuhn, J | 1 |
| Das, A | 1 |
| Banik, NL | 1 |
| Ray, SK | 1 |
| Brandsma, D | 1 |
| Stalpers, L | 1 |
| Taal, W | 1 |
| Sminia, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study Of ZD 1839 And Temozolomide For The Treatment Of Gliomas[NCT00027625] | Phase 1 | 0 participants | Interventional | 2002-01-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for temozolomide and Brain Edema
| Article | Year |
|---|---|
Bevacizumab as a treatment option for radiation-induced cerebral necrosis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemother | 2008 |
4 trials available for temozolomide and Brain Edema
| Article | Year |
|---|---|
A novel lecithin-based delivery form of Boswellic acids as complementary treatment of radiochemotherapy-induced cerebral edema in patients with glioblastoma multiforme: a longitudinal pilot experience.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Alkylating; Brain Edema | 2019 |
Chemotherapy alleviates subacute recurrent glioma-associated refractory cerebral edema by downregulating vascular endothelial growth factor.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Cisplatin; Dacarbazine; Down-Regulation; Female; Glioma; | 2014 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Anti | 2008 |
6 other studies available for temozolomide and Brain Edema
| Article | Year |
|---|---|
Evaluation of the Prognosis of Neuroglioma Based on Dynamic Magnetic Resonance Enhancement.
Topics: Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Contrast Me | 2020 |
Malignant transformation of a polymorphous low grade neuroepithelial tumor of the young (PLNTY).
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Fema | 2021 |
Hypercellularity Components of Glioblastoma Identified by High b-Value Diffusion-Weighted Imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Dac | 2015 |
Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Topics: Amino Acid Transport System X-AG; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal | 2016 |
Impact of Including Peritumoral Edema in Radiotherapy Target Volume on Patterns of Failure in Glioblastoma following Temozolomide-based Chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Coh | 2017 |
Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in human glioblastoma T98G and U87MG cells.
Topics: Acetazolamide; Apoptosis; Aquaporin 1; Brain Edema; Brain Neoplasms; Calpain; Carbonic Anhydrases; C | 2008 |